ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

אקסמסטאן טבע  25 מג ישראל - עברית - Ministry of Health

אקסמסטאן טבע 25 מג

abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

אקסאמסטאן אינובמד ישראל - עברית - Ministry of Health

אקסאמסטאן אינובמד

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

אקסמזין-ויט      ישראל - עברית - Ministry of Health

אקסמזין-ויט

vitamed pharmaceutical industries ltd - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

אקסמסטאן אקטביס 25 מג ישראל - עברית - Ministry of Health

אקסמסטאן אקטביס 25 מג

devries & co. ltd - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

אקסמסטאן טבע  25 מג ישראל - עברית - Ministry of Health

אקסמסטאן טבע 25 מג

abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

אקסמסטאן טבע  25 מג ישראל - עברית - Ministry of Health

אקסמסטאן טבע 25 מג

abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

אקסמסטן-תרימה ישראל - עברית - Ministry of Health

אקסמסטן-תרימה

trima trading (1961), israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

ארימידקס ישראל - עברית - Ministry of Health

ארימידקס

taro international ltd, israel - anastrozole - טבליות מצופות פילם - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

אנסטרוזול טבע ישראל - עברית - Ministry of Health

אנסטרוזול טבע

teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.